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Objectives: To explore the durability of three first-line tenofovir/emtricitabine-based regimens in combination
with atazanavir/ritonavir, efavirenz or lopinavir/ritonavir in HIV-1-infected patients.
Patients and methods: A retrospective, longitudinal, multicentre analysis of adult patients enrolled in the Antiretro-
viral Resistance Cohort Analysis (ARCA), a national prospective observational cohort of HIV-1-infected patients followed
up at more than 100 clinical and laboratory units in Italy. Patients eligible were those starting first-line antiretroviral
therapy between 1 June 2004 and 15 April 2011 and whowere followed up forat least 6 months. The primaryendpoint
was durability, defined as the time from antiretroviral therapy initiation to first treatment modification. Time-
dependent events were analysed by the Kaplan–Meier approach and the Cox proportional hazard model.
Results: There are 26000 HIV-infected patients in the ARCA database, of whom 1654 met study inclusion criteria. Six
hundred and thirty-nine (38.6%) received efavirenz, 321 (19.4%) received atazanavir/ritonavir and 694 (41.9%)
received lopinavir/ritonavir as a first-line regimen. Over a total observation period of 88 months, equivalent to more
than 2805 person-years of follow-up, 618 patients underwent treatment modification. Lopinavir/ritonavir, given
twice daily, was associated with a higher discontinuation rate than efavirenz- and atazanavir-based regimens
[hazard ratio (HR) 1.83, 95% confidence interval (CI) 1.56–2.15, P¼0.001]. Comparing the once-daily regimens, the
rate of discontinuation of efavirenz was higher than that of atazanavir/ritonavir (HR 1.39, 95% CI 1.06–1.83,P¼0.016).
Conclusions: Significant differences in treatment duration were observed among the three studied regimens. Once-
daily regimens exhibited greater durability than the twice-daily regimen. Among the specific regimens examined,
tenofovir/emtricitabine plus atazanavir/ritonavir showed the greatest durability.
Keywords: tenofovir/emtricitabine, durability, drug utilization, antiviral therapy, HIV/AIDS
Introduction
The introduction of highly active antiretroviral therapy (HAART)
as the standard treatment for HIV infection has greatly
reduced mortality and morbidity.1,2 Current practice guidelines
recommend the use of two nucleoside reverse transcriptase
inhibitors (NRTIs) combined with non-nucleoside reverse tran-
scriptase inhibitors (NNRTIs), protease inhibitors (PIs) or integrase
inhibitors for initial therapy of HIV-1 infection.3 – 5
Suppression of viral replication requires lifelong HAART, and in-
consistent use of medications can lead to development of
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resistance to one or more drugs included in the regimen, limiting
future treatment options and compromising patient outcome.6
However, adverse drug reactions, drug–drug interactions, co-
morbidities and socioeconomic barriers may influence the
safety, durability and efficacy of HAART.7 In clinical practice,
tenofovir/emtricitabine is the preferred backbone suggested
in all guidelines.3 – 5 Several studies have compared the efficacy
and tolerability of atazanavir/ritonavir versus efavirenz,8
atazanavir/ritonavir versus lopinavir/ritonavir9,10 and efavirenz
versus lopinavir/ritonavir,11,12 but there are few data directly
comparing the three drugs in combination with tenofovir/
emtricitabine in clinical practice.
The aim of this study was to assess the durability of the most
common first-line regimens—atazanavir/ritonavir, efavirenz and
lopinavir/ritonavir—in combination with tenofovir/emtricitabine
in previously antiretroviral-naive, HIV-infected adults followed
in a large Italian cohort.
Patients and methods
Study design
This was a retrospective, longitudinal, multicentre analysis of 1654
HAART-naive, HIV-infected adults enrolled in ARCA, a national observa-
tional cohort13 of HIV-1-infected patients followed up at more than
100 clinical and laboratory units in Italy. At the time of this study, data
from more than 26000 patients in the cohort were available. Patients
are enrolled in the ARCA database after giving informed consent to
provide their data for academic not-for-profit studies. The data include
demographics, hepatitis B and C virus status, AIDS-defining events, anti-
retroviral treatment, viral load, CD4+ T cell counts and HIV-1 genotype.
The ARCA initiative was started in 2002 and is compliant with the Dec-
laration of Helsinki. Each participating centre is answerable to a local
ethics committee that follows national (and European where applicable)
regulations.
Patients
Eligible patients were HIV-infected antiretroviral-naive adults in whom
first-line HAART was initiated between 1 June 2004 and 15 April 2011
and who were followed up for at least 6 months. Patients receiving first-
line treatments comprising tenofovir/emtricitabine as the backbone plus
efavirenz, lopinavir/ritonavir or atazanavir/ritonavir were extracted from
the ARCA database. Patients who discontinued first-line tenofovir/
emtricitabine-based HAART for a short period of time and then restarted
on the same regimen were excluded.
Study endpoints
The primary endpoint was the estimated duration of the three HAART
regimens compared in the study, defined as time from HAART initiation
to discontinuation of therapy due to any cause. The causes of treatment
change recorded included side effects of HAART, virological and/or im-
munological failure, pregnancy, poor compliance, HAART intensification,
regimen simplification and supervised interruption.
As this is an observational study, each prescribing physician estab-
lishes the modification of HAART in accordance with local guidelines,
although within internationally approved rules.
A switch from tenofovir/emtricitabine to tenofovir/emtricitabine/
efavirenz was not considered a treatment modification because it
reflects the delayed availability of the new fixed formulation of tenofovir/
emtricitabine/efavirenz in Italy in 2008.
Statistical analysis
For statistical analysis we considered the sex and age of patients, median
CD4 cell count and viral load at the time of starting HAART. The x2 test,
one-way analysis of variance (ANOVA) and Student’s t-test were used to
evaluate differences among groups.
Data were summarized as median and range in the case of quantita-
tive variables and as absolute frequencies and percentages in the case of
qualitative items. Time to event was analysed by the Kaplan–Meier
method and differences among curves were evaluated by the log-rank
test. A multivariable Cox regression model including sex, age, therapy
and baseline viral load (.100000 versus ,100000) was tested. Only
therapy and viral load were significant prognostic factors. Results are
given as HRs and 95% CIs and were adjusted for variables included in
the model. Using logistic regression, we examined the effect of calendar
year of starting HAART on the proportion of patients discontinuing each of
three HAART regimens.
Results
A total of 1654 antiretroviral-naive, HIV-infected patients were
included in the study. Among these patients, 639 (38.6%) received
an efavirenz-based first-line regimen, 321 (19.4%) received an
atazanavir/ritonavir-based first-line regimen and 694 (41.9%)
received a lopinavir/ritonavir-based first-line regimen. Baseline
characteristics of patients are listed in Table 1. Patients who
were prescribed lopinavir/ritonavir had more advanced disease
with a higher viral load and a lower CD4 cell count at baseline.
During our observation period of 88 months, we had 2805 person-
years of follow-up, in which 618 patients underwent treatment
modification. The most frequent reason for switching was drug
toxicity (Table 2). Treatment change occurred in 72 individuals
over 564 person-years in the atazanavir/ritonavir group, in 190
Table 1. Baseline demographics and disease characteristics
Efavirenz
(n¼639)
Atazanavir/
ritonavir
(n¼321)
Lopinavir/
ritonavir
(n¼694)
P
value
Age (years),
median (range)
39 (17–72) 41 (16–76) 40 (17–74) 0.12
Sex, n (%)
males 496 (77.6) 228 (71.0) 511 (73.6) 0.06
females 143 (22.4) 93 (29.0) 183 (26.4)
Co-infection, n (%)
HCV 101 (15.8) 68 (21.2) 116 (16.7) 0.11
HBV 58 (9.1) 33 (10.3) 66 (9.5) 0.83
Mode of transmission, n (%)
heterosexual 164 (25.7) 80 (24.9) 244 (35.2) 0.001
CD4+ cells/mL,
median (range)
283 (3–892) 236 (3–761) 167 (1–1242) 0.001
HIV-RNA copies/mL, n (%)
.100000 156 (37.9) 86 (50.6) 272 (54.1) 0.001
,100000 256 (62.1) 84 (49.4) 231 (45.9)
HCV, hepatitis C virus; HBV, hepatitis B virus.
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over 1046 person-years in the efavirenz group and in 356 over
1195 person-years in the lopinavir/ritonavir group. The results
of univariate analysis showed a statistically significant difference
in the duration of therapy between patients receiving atazanavir/
ritonavir or efavirenz and those receiving lopinavir/ritonavir
(P,0.0001). Furthermore, there was a statistically significant dif-
ference (P¼0.01) between atazanavir/ritonavir and efavirenz
(Figure 1). Treatment duration was also shorter with twice-daily
lopinavir/ritonavir than with the once-daily regimens (efavirenz
and atazanavir/ritonavir) (P¼0.0001; Figure 2). At 24 months,
50% of patients were receiving the twice-daily regimen com-
pared with 70% receiving once-daily regimens. At the time of
discontinuation, 55% of patients in the atazanavir/ritonavir
arm, 51% of patients in the efavirenz arm and 64% of patients
in the lopinavir/ritonavir arm had an HIV-RNA viral load below
50 copies/mL. Overall, durability on therapy was better for men
than for women (P¼0.03); this difference was greater in the
efavirenz group (P¼0.007). Moreover, durability on therapy did
not show significant differences according to the age of patients.
According to the multivariate analysis, the risk of treatment
discontinuation was greater for both efavirenz (HR 1.39,
95% CI 1.06–1.83, P¼0.016) and lopinavir/ritonavir (HR 1.98,
95% CI 1.44–2.72, P,0.001) than for atazanavir/ritonavir.
The risk of treatment discontinuation was higher with the twice-
daily regimen than with the once-daily regimens (HR 1.83,
95% CI 1.56–2.15, P,0.001). The risk of lower durability
was also higher among patients with a baseline viral load
.100000 copies/mL than in those with baseline viral load
,100000 copies/mL (HR 1.28, 95% CI 1.06–1.56, P¼0.007).
Table 3 shows the prevalence of starting therapy by calendar
year. The prevalence of discontinuation in the lopinavir/ritonavir
and efavirenz arms increased after 2006.
Discussion
In this analysis of 1654 patients starting their first HAART
regimen between 1 June 2004 and 15 April 2011, changes
to initial therapy with tenofovir/emtricitabine combined with
atazanavir/ritonavir, efavirenz or lopinavir/ritonavir were relative-
ly frequent. These findings are consistent with those of a previous
study.6,7 Initial treatment with atazanavir/ritonavir was associated
with a longer duration of treatment than first-line therapy with
lopinavir/ritonavir and, to a lesser extent, efavirenz. Our results
are in agreement with the data reported in the open-label,
non-inferiority study comparing once-daily atazanavir/ritonavir
with twice-daily lopinavir/ritonavir, each in combination with
tenofovir/emtricitabine, in 883 antiretroviral-naive participants.
Table 2. Causes of discontinuation
Drugs Adherence Failure Pregnancy Addition Interruption Simplification Toxicity Other Total
ATV/r 1 (1.4%) 4 (5.6%) 0 1 (1.4%) 3 (4.2%) 6 (8.3%) 18 (25.0%) 39 (54.2%) 72
EFV 5 (2.6%) 22 (11.6%) 5 (2.6%) 2 (1.1%) 5 (2.6%) 0 45 (23.7%) 106 (55.8%) 190
LPV/r 6 (1.7%) 13 (3.6%) 3 (0.8%) 6 (1.7%) 11 (3.1%) 91 (25.6%) 105 (29.5%) 121 (34%) 356
Total 12 (1.9%) 39 (6.3%) 8 (1.3%) 9 (1.5%) 19 (3.1%) 97 (15.7%) 168 (27.2%) 266 (43%) 618
ATV/r, atazanavir/ritonavir; EFV, efavirenz; LPV/r, lopinavir/ritonavir.
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Figure 1. Time to treatment modification during the observational period
after starting combination antiretroviral therapy. Top line, atazanavir/
ritonavir; middle line, efavirenz; bottom line, lopinavir/ritonavir.
1.0
0.8
0.6
Pr
op
or
tio
n 
on
 th
er
ap
y
0.4
0.2
0.0
0 24 48
Time (months)
72 96 120
Figure 2. Time to treatment modification during the observational period
after starting a once-daily or twice-daily regimen. Top line, once-daily
regimens (atazanavir/ritonavir or efavirenz plus tenofovir/emtricitabine);
bottom line, twice-daily regimen (lopinavir/ritonavir plus tenofovir/
emtricitabine).
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The analysis at 48 weeks9 and at 96 weeks10 demonstrated
similar virological and CD4+ T cell responses in participants receiv-
ing the two regimens.
Furthermore, our study reaffirms an increased risk of discon-
tinuation because of toxicity or simplification in the case of
lopinavir/ritonavir-based therapy.14,15 The vast majority of
patients who discontinued because of simplification were in
lopinavir/ritonavir arm; the reason for this choice was reduction
in the pill burden and dosing frequency.
In our study, patients on efavirenz also switched treatment
more frequently than those on atazanavir/ritonavir. Treatment
failure and adverse events were the main reason for discontinu-
ation of efavirenz; women in particular were more likely to
modify their efavirenz-based regimen (Figure 3).
We noted an increase in discontinuations by calendar year up
to 2006 for efavirenz and lopinavir/ritonavir. These observations
are likely to be attributable, at least in part, to approval of
atazanavir/ritonavir as a once-daily option for first-line therapy
in the USA and European Union.16
In agreement with several studies showing daily dosing is an
important component of regimen complexity, we found a signifi-
cant difference in the duration of once-daily (atazanavir/ritonavir
or efavirenz) versus twice-daily (lopinavir/ritonavir) combination
antiretroviral therapy.17,18 Once-daily dosing is considered a key
contributor to treatment success, improving quality of life, adher-
ence and patient satisfaction with therapy.19,20 In our study we
observed that patients with lower CD4+ T cell counts received
PI-based regimens more frequently. Our finding is not sup-
ported by statistical analysis, but in a retrospective longitudinal
analysis by Torti et al.,11 comparing lopinavir/ritonavir- and
efavirenz-based regimens, the group who received lopinavir/
ritonavir-containing regimens had significantly lower CD4+
counts at baseline. In these patients, the preference for first-line
treatment with lopinavir/ritonavir is justified by the ACTG 5142
study, in which patients receiving regimens containing lopinavir/
ritonavir experienced greater increases in CD4+ T cell counts
than did those receiving efavirenz plus two NRTIs.12
The difference we found in persistence with efavirenz treat-
ment between males and females (Figure 3) can be explained
by the lower weight in the latter group, resulting in increased fre-
quency of dose-dependent toxic effects.15,21
Toxicity remains a major cause of treatment discontinuation,
with more than one-quarter of patients stopping therapy
because of the occurrence of an adverse event. Although the
reason for treatment change is recorded, one limitation of our
analysis is an inability to determine the nature of the adverse
event as this type of data is not recorded in the ARCA database,
which is not focused on the toxicity of antiretrovirals. Another
limitation is the lack of data about interruption of tenofovir/
emtricitabine. In contrast, a strength of this study is the fact
that we have 7 years of data from multiple real-world practices
and we found a high discontinuation rate. As in a few large rando-
mized controlled clinical trials, we found atazanavir/ritonavir to
be a well-tolerated once-daily regimen and more durable than
lopinavir/ritonavir. Better-tolerated regimens or strategies to
improve tolerability remain a critical goal of antiretroviral therapy.
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